The Efficacy and Safety of Direct Oral Anticoagulants for The Treatment of Venous Thrombosis in Cancer Using Fuzzy PROMETHEE

Venous thromboembolism caused by cancer is continuing on the rise across the world. Cancer-related venous thromboembolism is a preliminary source of multiple comorbidities in cancer patients. Patients suffering from the complexity of cancer may necessitate critical care as a result of the malignancy. The administration of single-agent low molecular weight heparins for venous thromboembolism treatment is difficult due to the cost of the drug and the discomfort of the injections, both of which have a detrimental influence on health care quality which is why this study aimed at comparing direct oral anticoagulants by weighing various criteria using multi-criteria decision making (MCDM) models; specifically, fuzzy Preference Ranking Organization Method for Enrichment Evaluations (fuzzy PROMETHEE). The best preferable anticoagulant is claimed to be safe and effective for use in treating venous thromboembolism in cancer patients. From the results of this study, depending on the selected criteria, apixaban ranked as the first best preferable anticoagulant to be used in treating venous thromboembolism with a net flow; the difference between positive and negative outranking flow which provides a net ranking, of 0.0042 whereas rivaroxaban ranked fourth with a net flow of −0.0043 among the four compared alternatives. Fuzzy PROMETHEE was found to be effective and sensitive in providing the best choice by ranking the chosen alternatives depending on their considerable weighted criteria. The MCDM approach supports decision-makers and healthcare practitioners when making choices in the treatment phase.